Compare TANH & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TANH | GOVX |
|---|---|---|
| Founded | 2001 | 2001 |
| Country | China | United States |
| Employees | N/A | 17 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9M | 4.0M |
| IPO Year | 2013 | N/A |
| Metric | TANH | GOVX |
|---|---|---|
| Price | $0.47 | $1.34 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 318.7K | ★ 3.1M |
| Earning Date | 05-15-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.17 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.30 | $0.12 |
| 52 Week High | $2.59 | $4.40 |
| Indicator | TANH | GOVX |
|---|---|---|
| Relative Strength Index (RSI) | 50.78 | 43.35 |
| Support Level | $0.34 | $1.15 |
| Resistance Level | $0.47 | $2.00 |
| Average True Range (ATR) | 0.08 | 0.23 |
| MACD | 0.01 | -0.09 |
| Stochastic Oscillator | 27.50 | 17.19 |
Tantech Holdings Ltd manufactures bamboo charcoal-based products. The company, through its subsidiaries, is engaged in the production and distribution of household products along with a trading business, which involves the export of charcoal products. It also manufactures electric double-layer capacitors carbon materials and low-emission barbecue charcoal. Its product portfolio includes air purifiers and humidifiers, underfloor humidity control, pillows and mattresses, wardrobe deodorizers, mousepads, and wrist mats, refrigerator deodorant, and charcoal toilet cleaner disks. The company has two reportable segments: the Consumer Product segment, and the Electric Vehicle (EV) segment.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.